Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Monday that it has entered into a clinical trial collaboration and supply agreement with Japan's Eisai Co Ltd (TYO:4523) to evaluate fostrox in combination with lenvatinib in a Phase 2b study for second-line advanced liver cancer.

The combination therapy has shown encouraging anti-tumour activity and a manageable safety profile in a previous Phase 1b/2a study, with a median time to progression of 10.9 months.

Fostrox, an oral, liver-targeted treatment, has the potential to become a significant therapeutic option for patients with advanced liver cancer.

The collaboration with Eisai will allow Medivir to accelerate the development of fostrox and address a significant unmet medical need.